OBSV News and Press, ObsEva SA From 06/28/22

- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy - - Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as ...

Organon's P/E ratio was 6.5 at the end of Q1 2022, significantly lower than the pharmaceutical industry average. Viatris' revenue was $4,191.7 million in the first quarter of 2022, down 5.4% from a year earlier. Viatris' generic and brand drug sales have been declining year on yea...

Women’s health company ObsEva (NASDAQ:OBSV) announced on Friday that the European Commission (EC) granted marketing authorization for Yselty as a treatment for symptoms related to uterine fibroids (UF) in adult women of reproductive age. According to the company, the drug, also known a...

- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy - - Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sa...

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20 th World Congress - ...

GENEVA, Switzerland May 1 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Annette Clancy as Chair of the Board of Directors...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – May 19 , 202 2 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for wom...

ObsEva SA (OBSV) Q1 2022 Results Conference Call May 17, 2022 08:00 AM ET Company Participants Katja Buhrer - Chief Strategy Officer Brian O’Callaghan - Chief Executive Officer Brandi Howard - Chief Clinical Officer Will Brown - Chief Financial Officer Clive Bertram - Chief Commercial ...

ObsEva press release (NASDAQ:OBSV): Q1 GAAP EPS of -$0.14 beats by $0.11. ObsEva had cash and cash equivalents of $57.6 million at March 31, 2022 compared to $54.7 million at December 31, 2021. Shares +1.28% PM. For further details see: ObsEva GAAP EPS...

-Linzagolix for uterine fibroids: Received c onfirmation of p ositive CHMP opinion for marketing authorization application ; United States NDA PDUFA date in Q3:22 - -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with ad...